Desferrioxamine Administered Intravenously by Infusion Causes a Reduction in the Electroretinogram in Rabbits Anaesthetized with Urethane
- 1 July 1986
- journal article
- research article
- Published by SAGE Publications in Human Toxicology
- Vol. 5 (4) , 229-236
- https://doi.org/10.1177/096032718600500403
Abstract
In rabbits anaesthetized with urethane, intravenous infusion of the iron-chelating drug desferrioxamine causes a reduction in the amplitude of the electroretinogram. This is most pronounced for weak light intensities, but the change is more complex than a mere reduction in sensitivity. In experiments lasting up to 3 days the effect is reversible and is not accompanied by electron-microscopical histological changes.This publication has 8 references indexed in Scilit:
- Ocular changes in patients undergoing long-term desferrioxamine treatment.British Journal of Ophthalmology, 1984
- VISUAL LOSS IN PATIENT ON HIGH-DOSE SUBCUTANEOUS DESFERRIOXAMINEThe Lancet, 1984
- Delayed basal hyperpolarization of cat retinal pigment epithelium and its relation to the fast oscillation of the DC electroretinogram.The Journal of general physiology, 1984
- OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINEThe Lancet, 1983
- A modified ERG technique and the results obtained in X-linked retinitis pigmentosa.British Journal of Ophthalmology, 1983
- Desferrioxamine in ocular siderosis: a long-term electrophysiological evaluation.British Journal of Ophthalmology, 1980
- IMPROVEMENT IN IRON STATUS AND LIVER FUNCTION IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD WITH LONG-TERM SUBCUTANEOUS DESFERRIOXAMINEThe Lancet, 1979
- Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical ProgressBMJ, 1974